<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211211053351N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-25</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Preventive symbiotic administration on the incidence of allergic diseases in children aged 0 to 5 years</public_title>
      <acronym>MSS (Mashhad symbiotic study)</acronym>
      <scientific_title>Investigating the effect of preventive symbiotic administration on the incidence of allergic diseases in children aged 0 to 5 years, a clinical trial study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>400</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/69726</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization methods are used and
The randomization program is repeated until the desired balance is achieved.
The sample size is 200 people in each group, in the event that after the completion of the simple randomization program, if the inequality between the groups is more than 20 people, the creation of a random sequence will be repeated and the new program will replace the previous program.
  Researchers will repeat this process until receive the desired criterion. The number of samples allocated to each of the studied groups will be equal.
  The size of all blocks is equal and we will have two groups of 6 blocks in this trial (including 3 participants in the intervention group and 3 participants in the control group).
The randomization tool is also used from the software for generating random sequences (random allocation software), which in addition to simple randomization, these random sequence generating software are capable of generating random sequences using the block method, Blinding description: After selecting the samples, none of the participants will be aware of randomization and allocation to groups. Physicians will be given a table of pre-coded numbered numbers and patients will be entered into the study in order of table numbers. Therefore, the present study will be double-blind. Symbiotic drops and placebo drops manufactured by Zisttakhmir will be given to the control and intervention groups. And the placebo is the same in terms of shape, color and size and is delivered to the patient's parents in the package.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Allergic diseases in children.</hc_freetext>
      <i_freetext>Intervention group: After completing the research consent form, one symbiotic drop will be given to the family every month. Necessary training on how to store and use drops will be given. The dosage will be given as one cc per day for a period of 12 months..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamid Ahanchian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Fakouri Blvd, Mashhad, Khorasan Razavi Province, Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>91778 99191</zip>
        <telephone>+98 51 3871 3801</telephone>
        <email>Ahanchianh@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Fakouri Blvd, Mashhad, Khorasan Razavi Province, Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>91778 99191</zip>
        <telephone>+98 51 3871 3801</telephone>
        <email>tahereh.sadeghi@yahoo.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Be a resident of Mashhad city
Completing the consent form to participate in the research
Term neonatal 38 to 42 weeks
Normal weight at birth is 2500 to 3999 grams
According to Module 2.5: Risk factor questionnaire, the family is at risk for allergic diseases</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>5 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Abnormalities of the newborn in the cardiac, skeletal, nervous system</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J45.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Predominantly allergic asthma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After completing the research consent form, one symbiotic drop will be given to the family every month. Necessary training on how to store and use drops will be given. The dosage will be given as one cc per day for a period of 12 months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incidence of jaundice. Timepoint: The first month. Method of measurement: The bilirubin of newborns will be recorded up to 2 weeks and the management of jaundice, which includes hospitalization, use of medicine, blood exchange and its treatment measures, will be evaluated.</prim_outcome>
      <prim_outcome>Incidence of infantile colic. Timepoint: First month, third month of birth. Method of measurement: According to Wessel's diagnostic criterion, crying of a healthy infant for 3 hours a day, for 3 days a week and in 3 consecutive weeks is infantile colic, which is measured by the infantile colic scale questionnaire (ICS). This scale includes 22 items or questions that were scored from very little (with a score of 1) to very high (with a score of 5).</prim_outcome>
      <prim_outcome>Atopic dermatitis. Timepoint: The effect of Symbiotic use on the occurrence of allergic diseases in children will be evaluated at one month, 3 months, 12 months, 24 months, and 60 months. Method of measurement: The severity of the disease will be determined based on the SCORAD criteria, and this questionnaire will be completed by the interviewer and with the cooperation of the parents of infants or their caregivers.</prim_outcome>
      <prim_outcome>Allergic rhinitis. Timepoint: Third month, 12 months, 24 months, 60 months. Method of measurement: Diagnosis of allergic rhinitis based on history of rhinorrhea, nasal congestion and sneezing, itching, (if two or more of these symptoms are present for at least one hour on most days), along with at least one atopy criterion (family history of allergies, Elevated IgE or positive skin test is present Nose and throat examination will be used to rule out infectious rhinitis.​.</prim_outcome>
      <prim_outcome>ََAsthma. Timepoint: Third month, 12 months, 24 months, 60 months. Method of measurement: The severity of asthma and the frequency of asthma will be evaluated based on the ISAAC questionnaire.</prim_outcome>
      <prim_outcome>Respiratory Acute Infections. Timepoint: Third month,12 months, 24 months, 60 months. Method of measurement: Acute respiratory infections from a wide range of diseases such as throat infections, colds, and tonsillitis, flu, and lower respiratory tract diseases will be separated with the final diagnosis of pneumonia and bronchiolitis.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zisttakhmir Co</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-09</approval_date>
        <contact_name>Research Ethics Committees of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Knowledge and Health City, In the end of Shahid Fakouri Blvd (In front of Fakouri ٩۴), Mashhad - Iran Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
